GHRS
GH Research PLC
NASDAQ: GHRS · HEALTHCARE · BIOTECHNOLOGY
$20.53
+7.15% today
Updated 2026-04-30
Market cap
$1.26B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$9 – $25
Volume
0.2M
GH Research PLC (GHRS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $19000.00 | $47000.00 | $315000.00 | $315000.00 | $335000.00 |
| Gross profit | — | — | $-19000.00 | $-47000.00 | $-315000.00 | $-315000.00 | $-335000.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $296000.00 | $338000.00 | $8.55M | $20.48M | $29.82M | $35.02M | $38.73M |
| SG&A | $14000.00 | $108000.00 | $6.54M | $10.06M | $11.12M | $15.00M | $21.65M |
| Operating income | $-310000.00 | $-446000.00 | $-15.10M | $-30.55M | $-41.22M | $-50.31M | $-60.68M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-310000.00 | $-445000.00 | $-9.17M | $-22.41M | $-35.21M | $-38.60M | $-60.34M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-310000.00 | $-891000.00 | $-9.19M | $-22.46M | $-35.52M | $-38.91M | $-60.68M |
| Interest expense | $0.00 | $0.00 | $9000.00 | $8.10M | $723000.00 | $717000.00 | $462999.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-310000.00 | $-446000.00 | $-9.20M | $-22.46M | $-35.59M | $-38.96M | $-48.26M |
| Net income growth (YoY) | — | -43.9% | -1963.2% | -144.0% | -58.5% | -9.5% | -23.9% |
| Profit margin | — | — | — | — | — | — | — |